INSULIN THERAPY IN NWFP PAKISTAN

Authors

  • MAHMUD AHMAD

Abstract

The management of Type I and Type II DiabetesMellitus has improved because of tremendousimprovement in Insulins over the years, butunfortunately majority of patients in our countrycannot afford these, especially the human insulin, andare deprived of the benefits. Access to insulin shouldbe regular and uninterrupted.Insulin therapy has changed the outlook of Type I -IDDM from certain death to almost normal existence.The discovery of Banting and Best in 1921, was thegreatest breakthrough in this field. Since thencontinuous improvement in Insulins is taking place. InI980\s Recombinant DNA origin insulin came intouse. These insulins are less antigenic, purer, betterabsorbed and lesser doses are required as compared toanimal origin insulins. Human Insulin was firstproduct of biotechnology to enter the clinical Arena2.By 1950 exact structure of insulin molecule wasknown3. In developed countries the prognosis ofDiabetes has dramatically improved over last twentyyears with life expectancy approaching towardsnormal, especially in Denmark4.

References

Skyler JS Symposium Human Insulin or recombinant

DNA origin Diabetes care 5 (2) 1-186 1983.

Skyler JS Human Insulin after Ten years. Diabetes Care

,1-3,1993.

Bliss M History of insulin Diabetes care vol 16, Pg4-7

Cathelineau. G. Implementation of the declaration of

St. Vincent diabetic Metabol. 20: 337-4, 1994.

DCCT. The diabetes control and complications trial

Research group (DCCT) J. Am. Med. Assoc-276:

- 15,1996.

UKPDS. UK prospective Diabetes study. Intensive

blood glucose control with sulphonylureas or insulin

compared to conventional treatment and risk of

complications with Type 2 Diabetes. Lancet: 352:837-

; 1998.

Mbanya JC Insulin therapy in developing countries.

Implications of chronic shortages. Int: Diab:

Monitor. 12.1; 4-6,2000

Santiago JV Lessons from diabetes control +

complications trial. Diabetes: 42, 1549-54, 1993.

King H. Insulin, availability, affordability, and

harmonization. WHO Drug, 4;219-23, 19

Issue

Vol. 13 No. 3 (2001): JOURNAL OF AYUB MEDICAL COLLEGE, ABBOTTABAD

Section

ORIGINAL ARTICLE

License

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.